血液出血リスク (HOST-BR) による皮膚経冠動脈介入後の二重抗血小板治療:オープン,多センター,ランダム化臨床試験
Jeehoon Kang1, Kyung Woo Park1, Jung-Kyu Han1
1Seoul National University Hospital, Seoul, South Korea; Seoul National University College of Medicine, Seoul, South Korea.
Lancet (London, England)
|February 3, 2026
まとめ
高出血リスクの患者では,ステントを設置した後の1ヶ月のダブル抗血小板療法 (DAPT) は,3ヶ月のDAPTに劣らぬ効果を示さなかった. 高出血リスクでない患者では,3ヶ月のDAPTは12ヶ月のDAPTより劣らず,出血が減少しました.
科学分野:
- 心臓病学 心臓病学
- 介入性心臓病学 介入性心臓病学
- クリニック・トライアル 臨床試験
背景:
- 冠動脈ステント設置後の二重抗血小板治療 (DAPT) の最適な期間は,出血のリスクによって異なります.
- 証拠に基づいたDAPTの持続時間を確立することは,患者のアウトカムにとって極めて重要です.
研究 の 目的:
- 冠動脈ステント設置後のDAPTの最適な持続時間を評価するために,患者の出血リスクによって層分化.
- 高出血リスク (HBR) と非高出血リスク (非HBR) の集団における短期対長期のDAPT療法を比較する.
主な方法:
- オープン・ラベル,マルチセンター,ランダム化臨床試験で,薬剤排出ステントによる皮膚経冠動脈介入を受けた4897人の患者が参加した.
- 患者はHBRまたは非HBRグループに分類されました. HBR患者は1ヶ月のDAPTと3ヶ月のDAPTを受け,HBRでない患者は3ヶ月のDAPTと12ヶ月のDAPTを受けました.
- コプライマリーエンドポイントには,不良臨床事象,重大な不良心または脳事象,および1年後に処置可能な出血が含まれていました.
主要な成果:
- HBRグループでは,1ヶ月のDAPTは,3ヶ月のDAPTと比較して,クリーン不良臨床イベントの非劣等性を達成しなかった.
- 非HBRグループでは,3ヶ月のDAPTは,クリーン不良臨床イベントおよび主要な不良心または脳イベントの12ヶ月のDAPTに劣らずでした.
- 非HBRグループにおける3ヶ月のDAPT療法は,12ヶ月の療程と比較して,出血の減少において優越性を示した.
結論:
- 1ヶ月のDAPTは,冠動脈ステント設置後の高出血リスクを有する東アジア患者では不十分です.
- 3ヶ月のDAPT期間は,高出血リスクのない患者にとって,12ヶ月の期間よりも効果的で安全です.
- これらの発見は,個々の出血リスクプロファイルに基づいて個別化されたDAPT戦略を導く.
関連する概念動画
Clinical Trials
10.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.7K
Clinical Trials: Overview
5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Statistical Software for Data Analysis and Clinical Trials
1.6K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
435
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
435
Coronary Artery Disease III: Clinical Manifestations
383
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
383
Bleeding in Fresh Concrete
591
Bleeding in fresh concrete occurs when water from the mix rises to the surface. This happens because the mix's solid components fail to retain all the water as they settle, leading to separation where water collects at the top. The severity of bleeding can be measured by assessing the total settlement or by noting the decrease in height per unit height of concrete.
Bleeding can cause several issues in the concrete structure. Sometimes, the rising water gets trapped beneath large aggregate...
Bleeding can cause several issues in the concrete structure. Sometimes, the rising water gets trapped beneath large aggregate...
591


